You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
萊美藥業(300006.SZ)擬參設南寧匯友興曜股權投資基金合夥企業(有限合夥)
格隆匯 09-21 20:47

格隆匯 9 月 21日丨萊美藥業(300006.SZ)公佈,公司擬與北京同德同鑫投資中心(有限合夥)(“北京同德”)簽署《合夥協議》,參與投資設立南寧匯友興曜股權投資基金合夥企業(有限合夥)(暫定名,以工商行政管理部門最終核准的名稱為準)(“合夥企業”)。合夥企業擬定的總認繳出資額為人民幣1億元,公司認繳出資額為3000萬元。

公司此次參與投資的合夥企業直接投資武漢友芝友生物製藥有限公司後,友芝友生物將其正在研究開發的Y400(anti-VEGFA科類用藥眼科類用藥開發BsAb)濕性黃斑變性(nAMD)雙特異抗體藥物在中國區(含中國大陸、香港特別行政區、澳門特別行政區、台灣地區)的優先銷售代理權授予公司或其指定關聯方。此外,雙方還將探索進一步深度合作的方式,包括不限於合作拓展創新性研發項目、雙抗產品的市場代理銷售等。公司通過此次投資與友芝友生物開展合作,有利於公司進一步拓展業務領域,豐富眼科藥物品種,有利於公司在腫瘤、眼科等相關領域核心競爭力的提升,有助於公司經營發展和戰略目標的實現。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account